Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
about
Targeted therapy for advanced renal cell carcinomaBeyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaEnhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitorsNovel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialSequence of treatment in locally advanced and metastatic renal cell carcinomaCytoreductive surgery in the era of targeted molecular therapyCurrent management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in reviewPopulation pharmacokinetics of bevacizumab in cancer patients with external validationCytoreductive nephrectomy and its role in the present-day period of targeted therapy.Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvementThe impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic reviewProfile of tivozanib and its potential for the treatment of advanced renal cell carcinomaMetastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesLessons learned from the bevacizumab experienceSubverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancerTargeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapyTherapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinomaTargeted therapeutic strategies for the management of renal cell carcinomaCirculating biomarkers in advanced renal cell carcinoma: clinical applicationsApplication of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinomaEvaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinomaHypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaThe promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1Sunitinib in the treatment of metastatic renal cell carcinomaImmunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?Molecular mechanisms and clinical applications of angiogenesisImmunotherapy for metastatic renal cell carcinoma.Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkersEthical Issues in the Management of Renal Cell Carcinoma.Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer.Immunotherapy in genitourinary malignancies.The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future.Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and reviewAdaptive immunity in cancer immunology and therapeutics.
P2860
Q24242946-85D36458-E164-4480-ABAF-495379BA3FBAQ26766240-40276FB5-8357-4AB9-BAE8-491DE63D0096Q26768267-346BBDD9-C893-4FFA-9CDD-CBDA88866BB5Q26769884-0B58E996-6E55-41BA-8756-B7107691D2DBQ26773653-6104F647-BF2D-4B5F-A8CB-F425A4B2FC6EQ26774134-43E5904E-8990-4CAC-A36F-429D9149D331Q26774515-497E47EF-54A6-4908-87F2-AB26A10E718EQ26779580-F69E2BFD-0256-4369-90A9-2B98AEA9CD7AQ26783520-C9BFF398-F788-4C2D-8CA7-BC693F871737Q26796316-04307227-6C53-4763-B8CA-2301F6471031Q26801279-B98B3EBF-47DF-4D0D-9B0E-2160DE9ADF87Q26824086-64CDB7E3-7C79-4ACC-8CED-78C189718A94Q26827319-5BBF1947-19D6-4DD8-86CC-0F210AAD920BQ26852437-73D11EF5-8DFA-4662-A443-52335058F6ECQ26852509-2C1334E4-A329-47FD-8E39-0B2A9DF88B9DQ26852704-D4CC96BD-8540-4000-9AB1-73E632071B33Q26991589-31B62786-3767-410D-BCC1-D8B1DB04D19CQ27013665-2F3DEC64-C769-4A44-8CEF-3EEEF4F809F8Q27013846-DAC7098C-8A8E-4FCD-91B6-0C1A92D835C6Q27023770-C4B6DDFE-8726-4BB1-B97F-9847EFBA20B5Q27026961-7798F83C-139F-4BF4-A1AE-522AF98C7C60Q27028048-A733FF6D-5671-4FA0-AD8F-52ACF379BC8BQ28066747-5404CF17-0574-4837-A1AC-1ED506DB338EQ28069924-768ADA33-5388-466A-82E6-74D97D3982D3Q28072057-59A17B5F-6E03-414E-85E6-4F87083CCDF5Q28301672-7A7F34BD-9BF7-4F91-B469-FA4B1A80D2ABQ29547314-9DF63775-4CE5-4327-AA16-BCEA7E7DCE3FQ30234458-B988439A-A698-4B8B-ADF0-C167825CD8DBQ30399006-84A6A133-5E8B-4478-8529-AEE4888A38A8Q30472042-9D68EA90-C383-4A3C-8E2B-93E2168F9F24Q30724257-85105F68-7F67-4EE5-A9E9-39E7F7FA44F5Q31060162-E43E7C9E-27C0-499C-A0C9-0FD4B9CFD575Q33395466-3C17BC25-04BD-45FB-87FD-4B1938BEDDB7Q33408836-60BC28F8-C437-4C62-9752-528C52DB2C6CQ33593800-8F5FBDA9-FB07-4021-BB06-17C32D1745E3Q33705268-5934B39D-A0D3-4A73-B238-2E0B19A5B7FFQ33712944-544C4CBC-C2D6-4498-B422-849D22C9E89BQ33740717-511D7355-D122-4B91-A095-0B32AA7FAD3BQ33761655-05591CE9-71C0-4FEE-B1AE-3BEC0F181D46Q33893934-2EE04102-96D8-42B7-A0EC-A8C3D9B96786
P2860
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase III trial of bevacizumab ...... analysis of overall survival.
@ast
Phase III trial of bevacizumab ...... analysis of overall survival.
@en
Phase III trial of bevacizumab ...... etastatic renal cell carcinoma
@nl
type
label
Phase III trial of bevacizumab ...... analysis of overall survival.
@ast
Phase III trial of bevacizumab ...... analysis of overall survival.
@en
Phase III trial of bevacizumab ...... etastatic renal cell carcinoma
@nl
prefLabel
Phase III trial of bevacizumab ...... analysis of overall survival.
@ast
Phase III trial of bevacizumab ...... analysis of overall survival.
@en
Phase III trial of bevacizumab ...... etastatic renal cell carcinoma
@nl
P2093
P921
P356
P1476
Phase III trial of bevacizumab ...... analysis of overall survival.
@en
P2093
Alain Ravaud
Bohuslav Melichar
Emilio Bajetta
Joaquim Bellmunt
Sangeeta Jethwa
Sergio Bracarda
Sophie Golding
Sylvie Négrier
Vesna Sneller
P304
P356
10.1200/JCO.2009.26.7849
P407
P577
2010-04-05T00:00:00Z